GT201500053A - Composicion farmaceutica recubierta que contiene regorafenib - Google Patents

Composicion farmaceutica recubierta que contiene regorafenib

Info

Publication number
GT201500053A
GT201500053A GT201500053A GT201500053A GT201500053A GT 201500053 A GT201500053 A GT 201500053A GT 201500053 A GT201500053 A GT 201500053A GT 201500053 A GT201500053 A GT 201500053A GT 201500053 A GT201500053 A GT 201500053A
Authority
GT
Guatemala
Prior art keywords
pharmaceutical composition
regorafenib
composition covered
covered
same
Prior art date
Application number
GT201500053A
Other languages
English (en)
Spanish (es)
Inventor
Skrabs Susanne
Funke Adrian
Kresse Mayk
Oberdieck Ulrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201500053(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201500053A publication Critical patent/GT201500053A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GT201500053A 2012-09-06 2015-03-05 Composicion farmaceutica recubierta que contiene regorafenib GT201500053A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12183331 2012-09-06

Publications (1)

Publication Number Publication Date
GT201500053A true GT201500053A (es) 2015-10-12

Family

ID=46963450

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500053A GT201500053A (es) 2012-09-06 2015-03-05 Composicion farmaceutica recubierta que contiene regorafenib

Country Status (43)

Country Link
US (1) US20140065212A1 (enExample)
EP (2) EP2892507B1 (enExample)
JP (1) JP6445436B2 (enExample)
KR (1) KR102162036B1 (enExample)
CN (5) CN116392484A (enExample)
AP (1) AP2015008292A0 (enExample)
AR (1) AR092439A1 (enExample)
AU (1) AU2013312531B2 (enExample)
BR (1) BR112015004936B1 (enExample)
CA (1) CA2883767C (enExample)
CL (1) CL2015000544A1 (enExample)
CO (1) CO7310528A2 (enExample)
CR (1) CR20150114A (enExample)
CU (1) CU24244B1 (enExample)
CY (1) CY1118839T1 (enExample)
DK (1) DK2892507T3 (enExample)
EA (1) EA027685B1 (enExample)
ES (1) ES2623205T3 (enExample)
GT (1) GT201500053A (enExample)
HK (1) HK1214170A1 (enExample)
HR (1) HRP20170620T1 (enExample)
HU (1) HUE032758T2 (enExample)
IL (1) IL237350B (enExample)
IN (1) IN2015DN01673A (enExample)
JO (1) JO3479B1 (enExample)
LT (1) LT2892507T (enExample)
MA (1) MA37888B1 (enExample)
MX (1) MX359922B (enExample)
MY (1) MY176135A (enExample)
NZ (1) NZ705578A (enExample)
PE (1) PE20151005A1 (enExample)
PH (1) PH12015500460A1 (enExample)
PL (1) PL2892507T3 (enExample)
PT (1) PT2892507T (enExample)
RS (1) RS56019B1 (enExample)
SA (1) SA515360113B1 (enExample)
SG (1) SG11201501683WA (enExample)
SI (1) SI2892507T1 (enExample)
TW (1) TWI640329B (enExample)
UA (1) UA115994C2 (enExample)
UY (1) UY35006A (enExample)
WO (1) WO2014039677A1 (enExample)
ZA (1) ZA201501394B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
CN104586808B (zh) * 2014-12-27 2017-08-18 北京元延医药科技股份有限公司 抗肿瘤药物组合物
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN105136956A (zh) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 一种快速测定瑞戈非尼含量的方法
CN106880615A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种瑞戈非尼的口服固体制剂及其制备方法
CN106880607A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种含有瑞戈非尼的口腔崩解片及其制备方法
CN105496975B (zh) * 2015-12-17 2019-01-04 河南润弘制药股份有限公司 一种瑞戈非尼片剂及其制备方法
CN106913527A (zh) * 2015-12-28 2017-07-04 江苏先声药业有限公司 一种瑞戈非尼速释微丸及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
PT3630112T (pt) * 2017-06-02 2024-04-23 Bayer Healthcare Llc Combinação de regorafenib e nivolumab para tratamento de cancro
CA3103498A1 (en) * 2018-07-06 2020-01-09 Agios Pharmaceuticals, Inc. Ivosidenib forms and pharmaceutical compositions
CN111053751A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 瑞戈非尼的缓释片剂及其制备方法
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
CN112587485A (zh) * 2021-01-08 2021-04-02 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法
CN113018274A (zh) * 2021-03-10 2021-06-25 药源生物科技（启东）有限公司 一种含羟丙甲纤维素的药物组合物及其制备方法
TR2023002707A2 (tr) * 2023-03-10 2024-09-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Regorafenib içeren bir farmasötik bileşim.
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2529180T3 (es) * 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
CN1265793C (zh) * 2002-11-18 2006-07-26 杭州容立医药科技有限公司 左西替利嗪伪麻黄碱复方口服制剂及制备方法
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP2009519266A (ja) * 2005-12-15 2009-05-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト 炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア類
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
AU2007333302A1 (en) * 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
JP5351490B2 (ja) * 2007-10-25 2013-11-27 バイエル薬品株式会社 ニフェジピン含有有核錠剤およびその製法
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
ES2643693T3 (es) * 2011-05-20 2017-11-23 Astrazeneca Uk Limited Composición farmacéutica de rosuvastatina cálcica

Also Published As

Publication number Publication date
DK2892507T3 (en) 2017-05-01
IN2015DN01673A (enExample) 2015-07-03
EP2892507A1 (en) 2015-07-15
WO2014039677A1 (en) 2014-03-13
PH12015500460B1 (en) 2015-04-20
PH12015500460A1 (en) 2015-04-20
CR20150114A (es) 2015-05-11
KR20150048872A (ko) 2015-05-07
AR092439A1 (es) 2015-04-22
TW201414510A (zh) 2014-04-16
SA515360113B1 (ar) 2016-08-10
SI2892507T1 (sl) 2017-08-31
MX359922B (es) 2018-10-16
TWI640329B (zh) 2018-11-11
CA2883767C (en) 2018-11-13
HK1214170A1 (zh) 2016-07-22
CA2883767A1 (en) 2014-03-13
CO7310528A2 (es) 2015-06-30
NZ705578A (en) 2017-10-27
AP2015008292A0 (en) 2015-02-28
SG11201501683WA (en) 2015-04-29
IL237350B (en) 2020-11-30
CU20150020A7 (es) 2015-05-28
HUE032758T2 (en) 2017-10-30
CN116392485A (zh) 2023-07-07
JP2015527395A (ja) 2015-09-17
ZA201501394B (en) 2016-07-27
PE20151005A1 (es) 2015-06-27
RS56019B1 (sr) 2017-09-29
EP2892507B1 (en) 2017-02-01
CY1118839T1 (el) 2018-01-10
MA37888B1 (fr) 2019-08-30
UA115994C2 (uk) 2018-01-25
JP6445436B2 (ja) 2018-12-26
JO3479B1 (ar) 2020-07-05
BR112015004936B1 (pt) 2022-12-06
MY176135A (en) 2020-07-24
LT2892507T (lt) 2017-06-12
EA027685B1 (ru) 2017-08-31
CL2015000544A1 (es) 2015-08-21
CN116392484A (zh) 2023-07-07
PT2892507T (pt) 2017-05-02
PL2892507T3 (pl) 2017-09-29
HRP20170620T1 (hr) 2017-06-30
KR102162036B1 (ko) 2020-10-07
EA201590520A1 (ru) 2015-10-30
BR112015004936A2 (pt) 2017-07-04
EP3243508A1 (en) 2017-11-15
MA37888A1 (fr) 2018-07-31
ES2623205T3 (es) 2017-07-10
CN111249247A (zh) 2020-06-09
CN104902878A (zh) 2015-09-09
CU24244B1 (es) 2017-02-02
UY35006A (es) 2014-03-31
AU2013312531B2 (en) 2017-10-19
MX2015002815A (es) 2015-05-15
CN116392598A (zh) 2023-07-07
US20140065212A1 (en) 2014-03-06
AU2013312531A1 (en) 2015-03-12
IL237350A0 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
GT201400111A (es) Triazolopiridinas sustituidas
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
DOP2016000253A (es) Nuevos compuestos
MX2017007699A (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
NI201800071A (es) Compuestos de isoindol
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
EA201400444A1 (ru) Производные 2-оксопиперидинила
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
AR094063A1 (es) Uso de aclidinio, composicion farmaceutica y metodo para mejorar la actividad fisica en pacientes respiratorios
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol